Multiple antagonists of the VEGF signaling pathway such as the multikinase inhibitors sunitinib, pazopanib, axitinib and sorafenib and the monoclonal antibody to VEGFA, bevacizumab, are approved for treatment of patients with advanced RCC [1–4]. This evidence concerns the gene VEGFA and renal cell carcinoma.